Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.

Fabian Finkelmeier,Bernhard Scheiner,Catherine Leyh,J Best,T Fründt,C Czauderna,Alica K. Beutel,Dominik Bettinger,Johannes Weiß,Tobias Meischl,Fabian Kuetting,Dirk Waldschmidt,Michael Schultheiß,Thomas Jens Ettrich,Arndt Weinmann,Henning Wege,Marino Venerito,Christian M. Lange,Matthias Pinter,Oliver Waidmann

Cabozantinib in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort.

2020

e16668Background: The multikinase inhibitor cabozantinib has been approved by the European Medicines Agency in November 2018 for hepatocellular carcinoma (HCC) prior treated with sorafenib. We repo...

Keywords:

Oncology
Internal medicine
Cohort
Hepatocellular carcinoma
Pathology
Cabozantinib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations